Lessons for the United States from Pharmaceutical Regulation Abroad

Margaret Kyle
Additional contact information
Margaret Kyle: CERNA i3 - Centre d'économie industrielle i3 - Mines Paris - PSL (École nationale supérieure des mines de Paris) - PSL - Université Paris Sciences et Lettres - I3 - Institut interdisciplinaire de l’innovation - CNRS - Centre National de la Recherche Scientifique

Post-Print from HAL

Abstract: A American politicians from across the ideological spectrum have found a merican politicians from across the ideological spectrum have found a rare point of agreement: US drug prices are too high, and the government rare point of agreement: US drug prices are too high, and the government should do something about it. Figure 1 presents the results of a study of drug should do something about it. Figure 1 presents the results of a study of drug prices in different countries, which finds that overall US pharmaceutical prices, and prices in different countries, which finds that overall US pharmaceutical prices, and particularly prices of on-patent drugs, are several times higher than those in other particularly prices of on-patent drugs, are several times higher than those in other high-income countries such as France, Germany, Japan, and the United Kingdom high-income countries such as France, Germany, Japan, and the United Kingdom (Mulcahy, Schwam, and Lovejoy 2024). Such comparisons bolster the arguments of (Mulcahy, Schwam, and Lovejoy 2024). Such comparisons bolster the arguments of those advocating price controls or other government interventions in the United those advocating price controls or other government interventions in the United States. States.Why are policies around drug prices necessary? In other words, why do most developed countries rarely leave drug pricing to "the market" without government intervention? In all countries, pharmaceutical markets operate under conditions that differ substantially from the assumptions behind a competitive market that would equilibrate supply and demand based on price. These conditions reflect information problems, the specificities of healthcare markets, and the cost structure of drug development.First, pharmaceuticals are "credence goods": not only is their quality difficult for consumers to determine prior to consumption, but their effects are challenging to identify even after consumption. Regulation of entry, administered by the US Food and Drug Administration (FDA) and similar regulators like the European Medicines Agency (EMA), aims to reduce this information asymmetry. Consumers can be Lessons for the United States from Pharmaceutical Regulation Abroad

Date: 2025-05-01
References: Add references at CitEc
Citations:

Published in Journal of Economic Perspectives, 2025, 39, pp.53 - 78. ⟨10.1257/jep.20241418⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-05419166

DOI: 10.1257/jep.20241418

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().